WASHINGTON ( January 15 ) -- Today, President Trump unveiled  his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation  (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments.    Incubate's executive director, John Stanford, issued the following statement in response to the announcement:

WASHINGTON ( January 12 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital (VC) investors showing that policy -- not just scientific potential -- is playing an increasing role in how investors assess biotech opportunities. In other words, VCs aren't just watching the science; they're watching Washington.   The VCs surveyed invest in various companies, including early-stage startups and large, publicly traded firms. Respondents poi

WASHINGTON (December 19) –   Today, the Center for Medicare and Medicaid Innovation (CMMI) announced a proposed series of Medicare drug pricing demonstrations affecting some Part B  and Part D  medicines, respectively. The Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) demonstrations would significantly restructure Medicare drug reimbursement and coverage, pegging Medicare Part B and Part D drug prices to those

WASHINGTON ( December 2 ) -- Yesterday, the United States and the United Kingdom announced  a new agreement on pharmaceutical pricing as part of the Economic Prosperity Deal (EPD). The agreement is expected to increase the U.K.'s valuation of new medicines and expand its long-term investment in innovative therapies. The United States, in turn, committed to exempt U.K.-origin pharmaceuticals from any future Section 232 tariffs and to refrain from targeting U.K. pricing polici

WASHINGTON ( November 26) -- Yesterday, the Trump administration announced Maximum Fair Prices (MFPs) for the next 15 Medicare Part D drugs selected for price setting under the Medicare Drug Price Negotiation Program. The new prices take effect in January 2027.   Incubate's executive director, John Stanford, issued the following statement in response to the announcement:   " Today's announcement is another reminder of the fundamental flaws in existing federal drug-pricing p